神经退行性病
-
Figure 1｜Representation of deuterated dextromethorphan/quinidine.
Deuterated dextromethorphan/quinidine or AVP-786: Following the successful findings in the phase II trial with AVP-923, the FDA granted a fast-track designation to the deuterated sister compound, AVP-786 (Figure 1) to be directly investigated in phase III trials for the indication of agitation in AD. Deuteration of dextromethorphan/quinidine was shown to reduce the amount of quinidine needed to reach an effective plasma concentration of free dextromethorphan, thus reducing drug-drug interaction and cardiac side effects usually associated with quinidine. Aside from the pharmacokinetic alteration, deuteration of dextromethorphan was not shown to affect the selectivity and affinity for the receptors in the brain that are implicated in the neuropsychiatric effects .